Business Context and Reporting Period
Company: Integer Holdings Corporation (ITGR)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Integer is a leading medical device contract development and manufacturing organization (CDMO) serving Cardio & Vascular, Cardiac Rhythm Management, and Neuromodulation markets. The company operates as a single reporting segment with three product lines. In 2025, the company executed a "tuck-in" acquisition strategy, acquiring Precision Coating LLC, VSi Parylene, and Biocoat Incorporated to expand surface coating capabilities. The company is also in the process of exiting its Portable Medical market, with final sales expected in 2026.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Sales | $1,853.6 million | $1,716.6 million |
| Gross Profit | $500.4 million | $459.0 million |
| Gross Margin | 27.0% | 26.7% |
| Operating Income | $221.3 million | $208.2 million |
| Operating Margin | 11.9% | 12.1% |
| Net Income (Continuing Ops) | $102.8 million | $121.1 million |
| Diluted EPS (Continuing Ops) | $2.89 | $3.40 |
| Operating Cash Flow | $196.1 million | $205.2 million |
| Total Debt (Principal) | $1,207.3 million | $1,001.0 million |
| Cash and Equivalents | $17.2 million | $46.5 million |
| Working Capital | $538.1 million | $443.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 8.0% year-over-year, driven by a 16.6% increase in Cardio & Vascular sales (due to new product ramps and acquisitions) and flat growth in Cardiac Rhythm Management & Neuromodulation. "Other Markets" sales declined 26.9% due to the planned exit of the Portable Medical business.
- Profitability Decline: Despite higher operating income, Net Income from continuing operations decreased 15.1% to $102.8 million. This was primarily due to a $46.7 million induced conversion expense recorded in "Other loss, net" related to the exchange of 2028 Convertible Notes in Q1 2025.
- Acquisition Activity: The company completed three acquisitions in 2025 (Precision, VSi, Biocoat) with a total cash consideration of approximately $178.9 million, funded by borrowings. These contributed $58.7 million to 2025 sales.
- Debt Restructuring: In March 2025, the company issued $1.0 billion of 2030 Convertible Notes. Proceeds were used to exchange $383.7 million of 2028 Convertible Notes and pay down the revolving credit facility and term loan. Total debt principal increased to $1.2 billion.
- Share Repurchases: The company repurchased 698,356 shares for $50.0 million in 2025 under a new $200 million authorization. Subsequent to year-end, an additional $50 million accelerated share repurchase was initiated.
Guidance, Outlook, and Risks
- 2026 Outlook: Management expects 2026 sales growth to be impacted by lower sales related to three new products due to lower-than-anticipated market adoption, described as "highly unusual."
- Capital Expenditures: Expected to range between $95 million and $105 million in 2026, focused on manufacturing facility upgrades and IT systems.
- Convertible Notes Risk: The company holds $1.0 billion in 2030 Convertible Notes and $116.3 million in 2028 Convertible Notes. Conditional conversion features could be triggered if stock prices exceed specific thresholds, potentially requiring cash settlement and impacting liquidity.
- Customer Concentration: The top three customers (Abbott, Boston Scientific, Medtronic) accounted for 49% of total sales in 2025. Loss of business from these customers poses a material risk.
- Legal Proceedings: A putative securities class action lawsuit was filed in December 2025 alleging violations of securities laws regarding public disclosures. The company denies wrongdoing.
- Supply Chain & Geopolitics: Risks include raw material price fluctuations (precious metals), trade tariffs (specifically on imports from Mexico), and geopolitical tensions affecting global operations.
Investor Verification Checklist
- Induced Conversion Expense: Verify the non-cash nature of the $46.7 million expense and its impact on the effective tax rate (18.0%) and net income.
- Convertible Note Terms: Review the conversion triggers for the 2028 and 2030 notes to assess potential dilution or cash outflow risks if stock prices rise.
- Portable Medical Exit: Monitor the timeline and costs associated with the complete exit of the Portable Medical segment, expected to conclude in 2026.
- Acquisition Integration: Assess the revenue contribution and integration costs of the 2025 acquisitions (Precision, VSi, Biocoat) against the $178.9 million cash outlay.
- Customer Concentration: Evaluate the stability of relationships with the top three customers representing nearly half of total revenue.
- Share Repurchase Capacity: Confirm remaining capacity under the $200 million share repurchase program after the subsequent $50 million accelerated repurchase.